Chai Computer-Aided Design Suite for Molecules
Product · SaaS / cloud software · Education & training by Chai Discovery
Engineering molecules with artificial intelligence and atomic precision.
Chai Discovery's computer-aided design suite is a molecular engineering platform built for pharmaceutical and life sciences companies. It enables scientists to design new medicines on the computer by learning the underlying foundations of biochemical structure and interaction. The platform specializes in de novo protein and antibody design, allowing for the specification of complex formats and the targeting of challenging membrane proteins. By bypassing traditional high-throughput screening, the suite accelerates drug discovery programs with high success rates for antibodies and miniproteins.
- Languages
- English
- Antibody success rate
- >10%
- Miniprotein success rate
- >50%
- Experimentation cycle time
- <2 weeks
- Supported formats
- mAbs, VH-VL / VHH
Overview
Chai Discovery's computer-aided design suite is a molecular engineering platform built for pharmaceutical and life sciences companies. It enables scientists to design new medicines on the computer by learning the underlying foundations of biochemical structure and interaction. The platform specializes in de novo protein and antibody design, allowing for the specification of complex formats and the targeting of challenging membrane proteins. By bypassing traditional high-throughput screening, the suite accelerates drug discovery programs with high success rates for antibodies and miniproteins.
Molecular Design Controls
- Flexible antibody formats: Supports any framework sequence, including known frameworks or antibody formats such as mAbs, VH-VL, and VHH.
- Antigen state targeting: Enables targeting of specific antigen states for explicit design of agonism or antagonism.
- Membrane protein targeting: Facilitates targeting of membrane proteins without requiring lab-based workarounds like antigen mimetics.
- Epitope specificity: Allows users to choose a specific epitope on the target structure or let the model select one.
- Chemical modifications support: Capable of targeting epitopes with bound ligands or post-translational modifications like glycans.
Performance and Speed
- High antibody success rates: Achieves double-digit success rates exceeding 10% for antibodies to bypass extensive screening.
- Miniprotein efficiency: Delivers success rates greater than 50% for miniproteins.
- Rapid experimentation cycles: Allows users to go straight to characterization in less than 2 weeks, avoiding high-throughput screening.
- Target prompting options: Accepts public or private structures, or generates designs from predicted structures based on provided sequences.
- Advanced design criteria: Provides controls for species/ortholog specificity or cross-reactivity.
Specifications
- Antibody success rate
- >10%
- Miniprotein success rate
- >50%
- Experimentation cycle time
- <2 weeks
- Supported formats
- mAbs, VH-VL / VHH
Added by AntSpace from public sources (chaidiscovery.com).